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Abstract
Background. The survival of human immunodeficiency
virus (HIV)-infected patients has increased significantly
since the introduction of combination antiretroviral ther-
apy, leading to the development of important long-term
complications including cardiovascular disease (CVD) and
renal disease. Microalbuminuria, an indicator of glomeru-
larinjury,isassociatedwithanincreasedriskofprogressive
renaldeterioration,CVDandmortality.However,thepreva-
lence of microalbuminuria has barely been investigated in
HIV-infected individuals.
Methods. Based on three prospective urine samples in an
unselected nonhypertensive, nondiabetic HIV-positive co-
hort (n = 495), we analysed the prevalence of microal-
buminuria and compared the Caucasian share with that of
a nonhypertensive, nondiabetic population-based control
group (n = 2091). Significant predictors for microalbu-
minuria were analysed within the HIV-positive cohort.
Results. The prevalence of microalbuminuria was 8.7%
in the HIV-infected cohort, which is three to five times
higher than that in the general population. HIV-infected pa-
tients with microalbuminuria were older, and had higher
blood pressure, longer duration of HIV infection, higher
serum beta 2-microglobulin, higher serum creatinine and
a reduced glomerular filtration rate of ≤90 mL/min, com-
pared with those with normal albumin excretion. In mul-
tivariate analysis, systolic blood pressure, serum beta 2-
microglobulin and duration of HIV infection were found to
be independent predictors of microalbuminuria.
Conclusions. Our findings indicate that in addition to
haemodynamic effects, inflammatory activity may be im-
plicatedasacauseofthedevelopmentofmicroalbuminuria.
With respect to the increasing risk of developing CVD or
renal diseases and mortality, the high prevalence of mi-
croalbuminuria in HIV-infected individuals warrants spe-
cial attention.
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Introduction
The introduction of combination antiretroviral therapy
(cART) in the treatment of human immunodeficiency virus
(HIV) infection has led to a substantial decline in HIV-
related mortality and morbidity [1,2]. However, it has also
resulted in important short- and long-term adverse effects
[3]. Attention has mainly been focused on cardiovascular
disease (CVD) and there is evidence suggesting an associ-
ation between cART and coronary heart disease, especially
whenproteaseinhibitorsareinvolved[4–7].Theadverseef-
fect of cART on serum lipids has been suggested to at least
partially explain the increased rates of myocardial infarc-
tion [8], although other metabolic disturbances caused by
cART may also contribute [9,10]. In addition, endothelial
dysfunction has been proposed as a putative link between
HIV infection and CVD [11,12].
Kidney diseases are increasingly prevalent in the course
of HIV infection [13]. Today HIV-associated nephropathy
(HIVAN) is a considerable cause of end-stage renal dis-
ease in HIV-infected, African Americans [13], but other
histopathologicalrenaldiseases[14,15]affectingallethnic-
ities have also become more discernible. Moreover, HIV-
associated renal disease with overt proteinuria has been
associated with increased mortality [16,17]. Besides the
potential nephrotoxicity induced by cART [18], HIV it-
self may directly affect glomerular epithelial cells [19].
However, the pathophysiology of the various renal diseases
associated with HIV infection is not yet clear.
An increased urinary albumin excretion rate, even in
the microalbuminuric range, has been found to be an inde-
pendent risk factor for CVD and mortality in the general
population [20–22]. The pathophysiological mechanism
underlyingurinaryalbuminexcretionandtheincreasedrisk
ofCVDisnotfullyunderstood,althoughsystemicendothe-
lial dysfunction and inflammation has been implicated
C   The Author [2008].
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Fig. 1. Flow chart of the HIV-infected population in the study. Asterisk represents the estimated number of HIV-infected patients living in Oslo in
2004, based on the Norwegian Surveillance System for Communicable Diseases (MSIS).
[23,24]. Microalbuminuria has therefore gained increasing
recognitionasasimplemarkerofanatherogenicpropensity
[25]. Apart from a recent publication [26], there are few
studies of microalbuminuria in HIV-infected patients and
most of these have been undertaken in selected small
cohorts limited to the pre-cART era [27–29]. Nevertheless,
there is some evidence that microalbuminuria might
represent an early indicator of HIVAN [30]. Thus, early
detection of microalbuminuria could identify HIV-infected
subjects at high risk of developing CVD and even renal
diseases. To our knowledge, at the time of the initiation
of our study, no large prospective population-based cohort
study had investigated the prevalence of microalbuminuria
in an HIV-infected population.
The aim of this study was, first, to assess the prevalence
of microalbuminuria in an unselected HIV-infected cohort
in comparison with a population-based control group, and
second, to identify significant predictors of microalbumin-




outpatient clinic at the Department of Infectious Diseases,
Ullevaal University Hospital, Oslo, Norway, were invited
to participate. This is the main HIV clinic responsible for
treatmentofHIV-infectedpatientsinthecityofOslo,which
has ∼500 000 inhabitants. The patients attending the clinic
therefore represent an unselected group from the whole
city. No exclusion criteria were used. The study included
597HIV-positivepatientsenrolledbetweenMarch2004and
November 2005. Based on estimations from the Norwegian
Surveillance System of Communicable Diseases (MSIS),
they constitute ∼75% of the entire HIV-positive population
in Oslo (Figure 1). They were given written and oral infor-
mationaboutthestudyandtheattendingphysicianobtained
signed consent at a regular visit. The National Committee
ofMedicalResearchEthicsapproved thestudyandconces-
sionwasobtainedfromtheNationalDataInspectorate.The
subjects were followed as outpatients for up to 34 months.
A total of 55 patients were excluded because of dropout
after the initial visit (n = 26), i.e. impossibility to establish
contact, death (n = 12), moving abroad or to other clinics
in Norway (n = 11) or unwillingness to continue the study
after inclusion (n = 6). In addition, patients with previ-
ously diagnosed diabetes mellitus (n = 14) or hypertension
(n = 25) were excluded. The database was closed in Jan-
uary 2007. All patients were 20 years or older, and further
characteristics are presented in Table 1.
Control group
Control data from the large population-based Nord-
Trøndelag Health Study (HUNT) from 1995 to 1997,
in Norway (n = 2091), were used [31]. The subjects
constituted a healthy, nondiabetic and nonhypertensive
general population. Men and women were distributed
equally (47% versus 53%), with mean ages of 49.2 ±
15.6 and 48.7 ± 15.9 years, respectively. The population
was stable and ethnically homogenous with only a small
percentage (3%) of non-Caucasian origin [31].3132 M. Backken et al.
Table 1. Demographic and clinical data of HIV-infected subjects
Characteristic or laboratory value All (n = 495) Male (n = 354) Female (n = 141)
Age groups (years)a
<30 58 (11.7%) 23 (6.5%) 35 (24.8%)
30–39 158 (31.9%) 106 (29.9%) 52 (36.9%)
40–49 164 (33.1%) 119 (33.6%) 45 (31.9%)
>50 115 (23.2%) 106 (29.9%) 9 (6.4%)
Ethnicitya
Caucasian 348 (70.3%) 289 (81.6%) 59 (41.8%)
Black 114 (23%) 50 (14.1%) 64 (45.4%)
Asian 33 (6.7%) 15 (4.2%) 18 (12.8%)
Smokinga 211 (42.6%) 163 (46%) 48 (34%)
Cholesterol (mmol/L)b 5.0 ± 1.1 5.0 ± 1.1 5.0 ± 1.1
BMI (kg/m2)b 23.8 ± 3.4 23.8 ± 3.2 23.8 ± 3.9
HbA1c (%)b 5.2 ± 0.39 5.1 ± 0.35 5.2 ± 0.46
Hepatitis B positivea 22 (4.4%) 21 (5.9%) 1 (0.7%)
Hepatitis C positivea 46 (9.3%) 28 (7.9%) 18 (12.8%)
Duration since HIV test (years)b 7.3 ± 5.9 7.4 ± 5.9 7.2 ± 6.0
Beta 2-microglobulin (mg/L)b 2.1 ± 0.9 2.2 ± 0.9 2.0 ± 1.0
cARTa
Na¨ ıve throughout the study 141 (28.5%) 103 (29.1%) 38 (27.0%)
Na¨ ıve at study inclusion 22 (4.4%) 16 (4.5%) 6 (4.3%)
<2 years 162 (32.7%) 116 (32.8%) 46 (32.6%)
2–5 years 86 (17.4%) 56 (15.6%) 30 (21.3%)
>5 years 84 (17%) 63 (17.8%) 21 (14.9%)
HIV RNA (copies/mL)c 200 (0–31 000) 200 (0–35 500) 60 (0–14 000)
CD4 (109 cells/L)c 0.37 (0.24–0.55) 0.37 (0.25–0.56) 0.37 (0.22–0.53)
SBP (mmHg)b 129.5 ± 17.7 133.7 ± 17.0 119.1 ± 14.9
DBP (mmHg)b 80.2 ± 10.4 82.0 ± 10.5 75.7 ± 8.8
Creatinine (µmol/L)b 70.58 ± 14.5 75.3 ± 12.9 58.8 ± 11.4
GFR groups (mL/min)a
>90 411 (83%) 297 (83.9%) 114 (80.9%)
<90 81 (17%) 55 (16.1%) 26 (18.4%)
BMI, body mass index; cART, combined antiretroviral therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; GFR, glomerular filtration
rate.
aValues are the number of patients and (percentage).
bValues are the mean ± SD.
cValues are the median and (interquartile range).
Clinical examination and questionnaire
Three clinical visits were undertaken days to months apart,
when an HIV specialist physician investigated the patients.
Blood pressure was measured using a validated semiauto-
matic oscillometric device (Omron M4, Omron Matsusaka
Co. Ltd, Matsusaka, Japan). Well-trained nurses performed
two consecutive blood pressure measurements 2 min apart
using an appropriate cuff after the patient had rested in
a sitting position for 5 min in a quiet room. The average
of these measurements in duplicate was used for statisti-
cal analysis of systolic blood pressure (SBP) and diastolic
blood pressure (DBP). At the first clinical visit, height and
weight were measured to estimate the body mass index
(BMI) in kg/m2. A simple self-administered questionnaire
with yes/no answers was filled out regarding smoking and
intravenous drug-abuse habits, and knowledge of hyperten-
sion, diabetes, and cancer and hepatitis C status.
Urine samples
A urine sample was collected at each research visit for
determination of the albumin/creatinine ratio (ACR), a
measure for the urinary excretion rate of albumin [32].
Patients who underwent an antibiotic treatment for urinary
tract infection or had ongoing symptoms, where asked to
deliver a urine sample at the next visit. Urine albumin and
creatinine were measured using an immunoturbimetric
method (antihuman serum albumin antibody from Roche,
Basel, Switzerland) and an enzymatic method (Roche),
respectively. According to the ACR, based on at least
two urine samples, patients were categorized as having
normoalbuminuria (<2.5 mg/mmol), microalbuminuria
(2.5–30 mg/mmol) or macroalbuminuria (>30 mg/mmol).
A total of 460 patients delivered three urine samples each;
35 patients delivered two samples each and 3 patients
delivered only one. Patients who delivered only one urine
sample (n = 3) or had macroalbuminuria (n = 5) were ex-
cluded from the study. The same criterion for the definition
of microalbuminuria was used for the historical control
group [31]. In addition, glomerular filtration rate (GFR),
a measure of kidney function, was calculated based on the
Modification of Diet in Renal Diseases equations, which
take into account serum creatinine, age, sex and race [33].
Demographic and laboratory data
Age, gender, race, date of the patient’s first HIV-positive
test, transmission mode, CD4 cell count, HIV RNA,
serum beta 2-microglobulin, serum creatinine, cholesterol,Microalbuminuria and HIV 3133
starting date of cART, hepatitis B status and death date
were obtained from the local HIV database, updated
continuously from the patients’ records [34]. Data on
lipids and HbA1c were obtained directly from the patient
records. Duration since HIV test was calculated from the
first positive HIV test. With respect to cART exposure,
patients were allocated to different subgroups, while na¨ ıve
(untreated) patients were divided into those who were
untreated throughout the study and those who started
cART between the first and last clinical visits. HIV RNA
in EDTA plasma was quantified using polymerase chain
reaction amplification with a COBAS Amplicor HIV-1
Monitor Test (Roche Diagnostics, Branchburg, NJ, USA).
CD4 cell count was determined by routine flow cytometry
using TriTest CD4/CD8 with TruCount Tubes (Becton
Dickinson Biosciences, San Jose, CA, USA). All labora-
tory analyses were performed at the Department of Clinical
Chemistry at Ullevaal University Hospital. Data were
taken from the date nearest to the inclusion in the present
study.
Statistical methods
Patient data were collected in an EpiInfo database
(EpiInfoTM) for statistical analysis using SPSS software
(SPSS Inc., version 14.0, Chicago, IL, USA). Microalbu-
minuric and gender groups were compared for continuous
and categorical variables using Student’s t-test, the Mann–
Whitney U test and Pearson’s χ2 or Fisher’s exact test as
appropriate. Data are expressed either as the mean ± stan-
dard deviation (SD), as a number and percentage, or as
the median with the interquartile range for skewed data.
Predictors of microalbuminuria were evaluated using logis-
tic regression analysis and a backward stepwise procedure,
with P-to-enter < 0.1 and P-to-remove > 0.1, which are
the default values of the SPSS statistical package. Odds
ratio (OR) was determined by logistic regression analy-
sis or a χ2 test. The prevalence of microalbuminuria in
the Caucasian HIV-infected subjects was compared with
that in the control group defined by age and gender. All
P values were two sided and significance was accepted at
P < 0.05.
Results
Characteristics of an HIV-infected population
The cohort for this study included 495 HIV-infected pa-
tients (Table 1). The mean age at enrollment was 42.3 ±
10.3 years. Women were younger than men (36.8 ± 8.1
versus 44.5 ± 10.2 years, P < 0.0001) and 23% of the total
population were above 50 years of age. Males had been
infected mainly through homosexual activity (63.3%) and
were predominantly of Caucasian ethnicity, whereas half of
the females (49.6%) originated from high-endemic African
areas.Atthetimeofinclusioninthestudy,>60%ofthepa-
tients used cART, with well-maintained immune function,
as 85% had a CD4 cell count above 0.2 × 109 cells/L. This
rate did not differ between genders.
Microalbuminuria in HIV-infected patients
Microalbuminuria was present in 8.7% of the HIV-infected
population. Less than 1% of subjects had a GFR < 60
mL/min and 83% had a GFR ≥ 90 mL/min. In comparison
with subjects without microalbuminuria, subjects with mi-
croalbuminuria were older (47.6 ± 12.5 versus 41.8 ± 9.9
years,P<0.0001),hadhigherbloodpressure(SBP141.9±
27.8 versus 128.4 ± 15.9 mmHg, P < 0.0001; DBP 84.5 ±
12.9 versus 79.8 ± 10.1 mmHg, P = 0.005), longer dura-
tion of HIV infection (9.0 ± 5.5 versus 7.2 ± 5.9 years,
P = 0.05), higher levels of serum beta 2-microglobulin
(2.6 ± 1.3 versus 2.1 ± 0.9 mg/L, P = 0.002) and higher
serum creatinine (76.5 ± 23.1 versus 70 ± 13.3 µmol/L,
P = 0.005). In those individuals with GFR ≤ 90 mL/min,
microalbuminuria occurred more frequently (28.0 versus
15.2%, P = 0.021). In contrast, gender, race, smoking,
BMI, high-density lipoprotein or cholesterol level, pres-
ence of previous or current hepatitis B and C infection,
CD4 cell count and HIV RNA level did not differ between
those with and without microalbuminuria. Even when ex-
cludingpatientstreatedwithcART,CD4cellcountandHIV
RNA level did not differ between those with or without mi-
croalbuminuria. No statistically significant difference was
foundintheprevalenceofmicroalbuminuriabetweencART
groups based on the duration of therapy (<2 years, 8.6%;
2–5 years 10.5%; >5 years 9.5%). When analysing gender
separately, women with microalbuminuria showed no dif-
ferenceinage,SBP,DBP,HIVduration,creatinineandGFR
groups compared with those without microalbuminuria,
whereasmenwithmicroalbuminuriahadhighercholesterol
(5.4±1.6versus5.0±1.1mmol/L,P=0.038),butnodif-
ference in the beta 2-microglobulin level (2.4 ± 1.1 versus
2.2 ± 0.8 mg/L, P = 0.76), compared with those without
microalbuminuria.
Microalbuminuria in HIV-infected Caucasian subjects
compared with the general population
The prevalence of microalbuminuria was significantly
higher in the HIV-infected, Caucasian, male subjects than
in the population-based controls [31] in groups defined by
age and gender (Table 2). No statistically significant dif-
ference was found in the prevalence of microalbuminuria
betweenCaucasian,HIV-infectedwomen,<50yearsofage
compared to the population-based controls.
Predictors of microalbuminuria among HIV-infected
patients
Including the HIV-infected cohort in a multivariate analy-
sis (adjusted OR), with microalbuminuria as the dependent
variable and SBP, age, quartiles of HIV duration, serum
beta 2-microglobulin, serum creatinine and GFR groups as
independent variables, only SBP (P < 0.0001) and beta 2-
microglobulin (P = 0.001) were found to be predictive of
microalbuminuria (Table 3). Furthermore, the prevalence
of microalbuminuria was significantly higher in subjects
in the third quartile compared with the first quartile for
duration of HIV infection (P = 0.018). These results were
confirmed in a linear-by-linear association using an χ2 test
as a trend analysis for HIV duration quartiles in both the3134 M. Backken et al.
Table 2. Prevalence of microalbuminuria among 348 HIV-infected Caucasian men and women compared with 2091 subjects from the control groupa
Age groups HIV-infected patients Control group OR (95% CI) P
Total MA Percentage Total MA Percentage
nn nn
Men< 50 years 189 13 6.9 520 8 1.5 4.73 (1.8–12.70) 0.0002
Men 50–59 years 81 11 13.6 200 8 4.0 3.77 (1.34–10.78) 0.0038
Men 60–79 years 18 5 27.8 232 26 11.2 3.05 (0.87–10.22) 0.04
Women< 50 years 52 3 5.8 614 16 2.4 2.29 (0.51–8.75) 0.18
MA, microalbuminuria.
P-values were determined by the χ2 test.
Women aged > 50 years were not analysed because of the low number in the HIV-infected group (n = 7).
aFrom the HUNT study population.
Table 3. Predictors for microalbuminuria in HIV-infected subjects presented as unadjusted and adjusted odds ratios (n = 495)
Characteristic or laboratory value Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age (years) 1.05 (1.02–1.08)a 1.007 (0.97–1.05)c
SBP (mmHg) 1.04 (1.02–1.05)a 1.03 (1.02–1.05)a
DBP (mmHg) 1.04 (1.01–1.07)be
Duration since HIV test, quartiles (years)
1st Reference Reference
2nd 1.66 (0.53–5.2)c 1.89 (0.56–6.34)c
3rd 3.78 (1.35–10.6)d 3.76 (1.26–11.2)d
4th 2.79 (0.96–8.1)c 2.67 (0.88–8.14)c
Beta 2-microglobulin (mg/L) 1.57 (1.17–2.1)b 1.69 (1.23–2.33)b
Creatinine (µmol/L) 1.03 (1.01–1.05)b 1.0 (0.97–1.02)c
GFR groups (mL/min)
>90 Reference Reference
<90 2.75 (1.38–5.48)d 1.91 (0.91–3.99)c
SBP, systolic blood pressure; DBP, diastolic blood pressure; GFR, glomerular filtration rate.
Values were determined by logistic regression analysis. The candidate variables were defined with P-to-enter < 0.1.
aP < 0.0001; bP < 0.01; cP < 0.05; dP > 0.05.
eDBP excluded because of the high Pearson correlation (>0.7) between SBP and DBP.
total population (P = 0.019) and men (P = 0.003), but not
in women (P = 0.51), and for beta 2-microglobulin quar-
tiles in the total population (P = 0.035) and women (P =
0.027), but not for men (P = 0.3). The prevalence of mi-
croalbuminuria in relation to duration of HIV infection and
beta 2-microglobulin is presented for the total population
and for men and women separately in Figure 2a and b.
Discussion
The prevalence of microalbuminuria was 8.7% in this un-
selected cohort of HIV-infected patients and 9.2% in the
Caucasianpatientsonly,whichis2–4.7timeshigherthanin
thegeneralpopulation.TheassociationbetweenHIVinfec-
tion and microalbuminuria based on a single urine sample
has previously been observed in selected study populations
in the pre-cART era, with a prevalence ranging from 19
to 34% [27–29]. A recently published multicenter study,
with selection bias of significant lipodystrophy as an en-
try criterion and not primarily aimed at the investigation of
microalbuminuria, found a fivefold higher rate of microal-
buminuria in HIV-infected patients than in a matched, but
not population-based, control group [26], a result similar to
ours despite disparities in study design and urine sampling
procedures. In our study, the presence of microalbuminuria
was based on three consecutive urine analyses collected
prospectively. The importance of taking repeated measure-
ments has been emphasized by Romundstad et al. [35],
as albumin excretion may vary substantially and single-
sample measurements lead to an overestimation of the true
prevalence of microalbuminuria. To further minimize such
overestimation, patients with known diabetes, hypertension
or macroalbuminuria were not included in the HIV cohort
or in the control group. Other strengths of our study are
the unselected, single-center population, and standardized
investigation with robust and repetitive measurements of
urinary albumin excretion, using the same laboratory for
all analyses.
Blood pressure was a major determinant of albumin
excretion in our study, as has previously been demonstrated
for other populations [36,37] and in an HIV-infected cohort
[26]. Furthermore, serum beta 2-microglobulin, an inflam-
matory marker of HIV Immunoactivity [38], emerged as
an independent predictor for urinary albumin excretion.
This novel finding may suggest that other pathophysi-
ological mechanisms beyond the haemodynamic effect
may be linked to microalbuminuria in the HIV-infectedMicroalbuminuria and HIV 3135
Fig. 2. (a) Distributions of the prevalence of microalbuminuria (MA) related to the quartile durations since HIV test in the total population (n = 495),
men (n = 354) and women (n = 141). (b) Distributions of the prevalence of MA related to the quartile levels of serum beta 2-microglobulin in the total
HIV-infected population (n = 493), men (n = 353) and women (n = 140).
state. This is further supported by the observation that
subjects with microalbuminuria had longer durations
of HIV infection than those without microalbuminuria.
Inflammatory activity as a cause of microalbuminuria
has been observed in nondiabetic subjects with cancer,
inflammatory bowel disease and rheumatoid arthritis as
well as in subjects with type 2 diabetes mellitus [39].
Moreover, endothelial dysfunction maintained by various
inflammatory processes has been proposed as a possible
causeofmicroalbuminuria [40].Therefore, wehypothesize
that microalbuminuria could depend on some chronic
inflammatory process induced by HIV infection itself, not
excluding the possibility that surrogate parameters of the
immune function may play a role, even though we did not
find any association between CD4 cell count or HIV RNA
and microalbuminuria in the present study.
In this study, we could not show any association be-
tween the use of cART and microalbuminuria, which is in
harmony with the results by Szczech et al. [26]. Nor did
we observe significant differences between the duration of
cART and microalbuminuria. Several studies have demon-
strated increased CVD in HIV-infected patients receiving
cART [5–7,41]. Consequently, metabolic side effects in-
ducedbycARThavebeenimplicatedinthepathophysiolog-
ical mechanism leading to CVD, but endothelial dysfunc-
tion may also be an important contributor [42]. Endothelial
dysfunction has been proposed as a link between the pres-
ence of microalbuminuria and the increased risk of CVD
in selected populations as well as in the general population
[23,31,43], but remains to be evaluated in the HIV-infected
population. However, be that as it may, microalbuminuria
could serve as an early marker of enhanced cardiovascular
risk and even of renal complications in the HIV-infected
population as has been reported for other populations [30].
In a univariate analysis, microalbuminuria was linked
to renal function, even if this was not maintained in a
multivariate analysis. In contrast, Szczech et al. found no
difference in serum creatinine or GFR in microalbuminuric
compared to normoalbuminuric HIV-infected individuals
[26]. On the other hand, in a selected South African
HIV cohort where persistent microalbuminuric patients
underwent renal biopsy, microalbuminuria was found to
be an early indicator of renal disease [30]. A variety of
renal diseases may occur and constitute an increasingly
frequent complication during the course of HIV infection
[13], hence the presence of microalbuminuria cannot be
neglected.
We used a historical but population-based and nondi-
abetic control group [31]. During the 10-year time span,
there has most likely been a change in awareness and treat-
ment of microalbuminuria in diabetic subjects in Norway.
However, little change in healthcare has occurred in the
nondiabetic population. The age distribution of subjects
younger than 50 years was slightly different compared with
our cohort. This resulted in higher proportions of younger
menandolderwomeninthecontrolgroupthaninourstudy
population. Furthermore, the ethnicity differed between the
HIV-infected group and the control group, as the propor-
tion of immigrants was higher in the HIV-infected group.
Therefore, comparison to the population-based control
group was limited to Caucasian HIV-infected patients. To
establish a separate control group, including groups of
different ethnicity, for this study would most likely not
be possible or require an immense effort and would seem
rather futile given that a very meticulous investigation
had already been undertaken in Norway [21,31,35,44].
Nevertheless, ethnicity did not affect the results in this
study.
In conclusion, the prevalence of microalbuminuria in
Caucasian,nondiabetic,nonhypertensiveHIV-infectedsub-
jects was found to be 2–4.7 times higher than in a healthy,
nondiabetic and nonhypertensive control population. The
durationofHIVinfection,serumbeta2-microglobulinlevel
and SBP were independent predictors of microalbumin-
uria in our HIV cohort. Thus, we suggest that the mecha-
nisms causing microalbuminuria in HIV-infected subjects
are linked not only to haemodynamic factors, but also
to some yet unknown factor related to the HIV infec-
tion,possiblyendothelialdysfunction.Thismightassociate
microalbuminuria to the increased risk of CVD seen in3136 M. Backken et al.
HIV-infectedsubjects.However,theprognosticandclinical
significance of microalbuminuria in HIV-infected patients
is not yet known and prospective studies addressing this
issue are clearly needed.
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